



**THE FOUNDATION
FOR SECURE
MARKETS®**

#52802

Date: July 11, 2023

Subject: Clovis Oncology, Inc. - Contract Adjustment/Acceleration of Expirations
Option Symbol: CLVSQ
Date: 07/11/2023

On June 16, 2023, the United States Bankruptcy Court for the District of Delaware confirmed the Third Amended Joint Chapter 11 Plan of Liquidation ("Plan") for Clovis Oncology, Inc. (CLVSQ). The Plan became effective on July 11, 2023, and Clovis Oncology, Inc. shares were canceled. If the Liquidation Trustee issues Interest CVRs, CLVSQ shareholders as of April 18, 2023 will be entitled to receive a pro rata portion of non-transferable Interest CVRs.

NOTE: The Interest CVR represents a non-transferable contractual right to receive a possible payment as described in the Plan. CLVSQ options will not be adjusted to call for the delivery of the CVRs.

Contract Adjustment

Effective July 11, 2023, existing CLVSQ options are adjusted to no longer call for the delivery of CLVSQ shares upon exercise.

The option symbol CLVSQ will not change.

In settlement of CLVSQ exercise/assignment activity, a CLVSQ put exerciser (or call assignee) will receive a cash payment of the full aggregate strike price amount on the exercise settlement date. A CLVSQ put assignee (or call exercise) will pay this amount on the exercise settlement date. Settlement will take place through OCC's cash settlement system on the second business day after exercise.

Since CLVSQ options are American-style, they are exercisable at the election of the holder. Expiration processing for CLVSQ options will take place in the normal fashion, including automatic exercise thresholds.

Acceleration of Expirations

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of Clovis Oncology, Inc. options whose expiration dates are after 7-21-2023 will have their expiration dates advanced to 7-21-2023. Expiration dates occurring before 7-21-2023 (e.g., Flex options) will remain unchanged.

All Clovis Oncology, Inc. options will utilize a \$.01 exercise threshold.

Option Symbol: CLVSQ

Existing Expiration: All months

New expiration date: 7-21-2023

Existing American-style Clovis Oncology, Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.